What is the clinical evidence from this study?

Study design: Review. Population: Myocarditis.

What does this research mean for the field?

Myocarditis pathogenesis is driven by complex innate and adaptive immune dysregulation, necessitating precision immunomodulatory therapies to mitigate chronic inflammation and adverse remodeling. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To synthesize the cellular and molecular mechanisms driving myocardial inflammation in myocarditis and highlight emerging biomarkers and targeted immunomodulatory strategies.

June 23, 2026Frontiers in Cardiovascular MedicineOpen Access

Myocardial inflammation in myocarditis: mechanisms and therapeutic targets

View Full Paper

Ask AI

Bookmark

Key result

Immune dysregulation drives myocarditis pathogenesis, highlighting targeted immunomodulatory therapies and emerging biomarkers.

Key Points

To synthesize the cellular and molecular mechanisms driving myocardial inflammation in myocarditis and highlight emerging biomarkers and targeted immunomodulatory strategies.
Narrative review synthesizing immunopathological evidence across infectious, autoimmune, and drug-induced forms of myocarditis.
Evaluation of innate and adaptive immune cascades, pattern-recognition receptor signaling, cytokine networks, and fibrotic remodeling pathways.
Assessment of emerging inflammatory biomarkers (including microRNAs, S100A8/S100A9 alarmins, sST2, and galectin-3) for risk stratification.
Innate immune activation via pattern-recognition receptors (such as Toll-like receptors and the NLRP3 inflammasome) triggers early myocardial infiltration by neutrophils, natural killer cells, and inflammatory monocytes.
Imbalance in Th1/Th2 immunity, dysregulation of the Th17/Treg axis, and molecular mimicry with cardiac antigens (such as alpha-myosin heavy chain) perpetuate chronic inflammation and adverse fibrotic remodeling toward dilated cardiomyopathy.
Emerging immune-derived indices and alarmins offer potential for improved risk stratification and disease monitoring to guide targeted precision immunomodulation.

Structured PICO

Population

Patients with myocarditis and inflammatory cardiomyopathies, including infectious, immune-mediated, and toxic/drug-related etiologies.

Understanding the immunopathological mechanisms of myocarditis bridges insights with clinical translation, highlighting the potential for inflammation-guided risk stratification and targeted immunomodulatory strategies.

Limitations

The level of evidence supporting emerging biomarkers and immunomodulatory approaches remains heterogeneous.
Clinical evidence supporting the diagnostic or therapeutic application of miRNAs in myocarditis remains limited.
Robust human myocarditis data for targeted anti-inflammatory therapies remain limited, underscoring the need for mechanism-driven clinical trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Does not support immunomodulatory therapy changes in myocarditis; leaves open targeted strategies pending prospective trials.

Cite This Study

Madaudo et al. (2026) conducted a review in Myocarditis. Inflammatory mechanisms and immune dysregulation play a central role in myocarditis pathogenesis, highlighting the potential for emerging biomarkers and targeted immunomodulatory therapies.

synapsesocial.com/papers/6a7a0135756812e395895fad https://doi.org/10.3389/fcvm.2026.1821475

Topics

Molecular Mechanisms of Cardiac Remodeling

View Full Paper

Ask AI

Bookmark

Myocardial inflammation in myocarditis: mechanisms and therapeutic targets

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Topics

Myocardial inflammation in myocarditis: mechanisms and therapeutic targets

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider